指南与共识心力衰竭与心肌病

射血分数改善的心力衰竭患者指南导向药物治疗与结局

Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction.
指南 / 共识 · J Am Coll Cardiol · 2025-01-01

在Kaiser Permanente北加州系统2013–2022年新诊断HFrEF患者中,30.6%在12个月内出现射血分数改善(HFimpEF)。HFimpEF患者的心衰恶化率和死亡率仍较高,但低于持续性HFrEF;GDMT使用在改善后多数类别略有下降,停药与更高临床风险轻度相关。

要点

  • HFrEF患者12个月内约30.6%转为HFimpEF,但仍存在显著临床风险。
  • HFimpEF患者心衰恶化率17.4/100人年,死亡5.7/100人年,均低于持续性HFrEF。
  • HFimpEF后GDMT多数类别使用略有下降,停药与更高风险轻度相关。

核心结论

  • 相当比例HFrEF患者射血分数改善转为HFimpEF,但仍有显著临床风险。
  • 需进一步研究持续GDMT依从和治疗优化对HFimpEF结局的影响。

研究设计与样本

  • 回顾性队列研究,纳入Kaiser Permanente北加州系统2013年1月至2022年12月新诊断HFrEF患者28,292例,平均LVEF 31.1%±7.4%。
  • HFimpEF定义为12个月内随访LVEF>40%且绝对改善>10%。

主要发现

  • 8,656例(30.6%)在12个月内出现HFimpEF。
  • HFimpEF患者心衰恶化率17.4/100人年(95%CI 16.9-18.0),持续性HFrEF为34.1/100人年(95%CI 33.5-34.6),HR 0.58(95%CI 0.55-0.61)。
  • HFimpEF患者死亡率5.7/100人年(95%CI 5.4-6.0),持续性HFrEF为11.0/100人年(95%CI 10.7-11.3),HR 0.52(95%CI 0.49-0.56)。
  • 研究期间HFimpEF后多数药物类别GDMT使用略有下降,停用GDMT与更高临床风险轻度相关。

临床怎么用

  • HFimpEF患者应视为仍具临床风险人群,需继续监测心衰恶化与死亡风险。
  • 关注GDMT在射血分数改善后的维持情况,避免不必要的停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of heart failure with improved ejection fraction (HFimpEF) is anticipated to increase with the availability and implementation of novel pharmacotherapy for heart failure with reduced ejection fraction (HFrEF). However, there are limited data on contemporary epidemiology, management, and outcomes for this clinical entity. OBJECTIVES: The aim of this study was to describe epidemiology, guideline-directed medical therapy (GDMT), and outcomes among patients with HFimpEF across a large, diverse, multisite integrated health care delivery system. METHODS: Patients who were diagnosed with incident HFrEF between January 2013 and December 2022 across the Kaiser Permanente Northern California integrated health care delivery system were identified. Rates of incident HFimpEF, defined as HFrEF with a follow-up ejection fraction >40% and with >10% absolute left ventricular ejection fraction improvement within 12 months of incident HFrEF diagnosis, were identified. GDMT was examined at the time of incident HFrEF and HFimpEF and in the year following HFimpEF. Rates of worsening heart failure events and death were examined and compared among those with HFimpEF vs persistent HFrEF. RESULTS: In total, 28,292 patients with newly diagnosed HFrEF (mean left ventricular ejection fraction 31.1% ± 7.4%) were identified, of whom 8,656 (30.6%) experienced HFimpEF within 12 months. Use of GDMT marginally decreased in most medication categories after incident HFimpEF during the study period. Rates of worsening heart failure were 17.4 per 100 person-years (95% CI: 16.9-18.0 per 100 person-years) among patients with HFimpEF vs 34.1 per 100 person-years (95% CI: 33.5-34.6 per 100 person-years) among patients with persistent HFrEF (HR: 0.58; 95% CI: 0.55-0.61 per 100 person-years). Rates of death were 5.7 per 100 person-years (95% CI: 5.4-6.0 per 100 person-years) and 11.0 per 100 person-years (95% CI: 10.7-11.3 per 100 person-years) among patients with HFimpEF and those with persistent HFrEF, respectively (HR: 0.52; 95% CI: 0.49-0.56). Withdrawal of GDMT was modestly associated with greater clinical risk. CONCLUSIONS: A significant percentage of patients with HFrEF experience improvement in ejection fraction, transitioning to HFimpEF, yet remain at significant clinical risk. Further research is needed to evaluate the impact of sustained GDMT adherence and therapeutic optimization on outcomes in patients with HFimpEF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Min, Go, Lee, et al. Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction. J Am Coll Cardiol. 2025. PMID: 40738561. doi:10.1016/j.jacc.2025.05.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。